Loading
Please wait while we load your information from QuoteMedia.
Loading
Please wait while we load your information from QuoteMedia.
Please wait while we load your information from QuoteMedia.
Please wait while we load your information from QuoteMedia.
Please wait while we load your information from QuoteMedia.
As of January 23, 2025 • 1:00 AM ET
As of January 23, 2025 • 1:00 AM ET
Date/Time | Source | News Release |
---|---|---|
01/21/2025 06:27 PM EST | SeekingAlpha | Solid Biosciences: Differentiating Factors Of SGT-212 To Set Itself Apart |
01/08/2025 10:24 AM EST | Zacks | SLDB Stock Up as FDA Clears IND for SGT-212 in Friedreich's Ataxia |
01/07/2025 05:23 PM EST | SeekingAlpha | Solid Biosciences stock jumps 11% post-market on FDA update |
01/03/2025 05:49 PM EST | SeekingAlpha | Larimar Therapeutics: Positive Friedreich's Ataxia Data Can Only Get Better |
12/17/2024 09:14 AM EST | KlickAnalytics | LRMR Price Target Alert: $15.00. Issued by H.C. Wainwright |
12/17/2024 07:00 AM EST | KlickAnalytics | Buy Recommendation Issued On LRMR By H.C. Wainwright |
11/27/2024 04:31 AM EST | US Earnings Reports | Expected earnings - Larimar Therapeutics Inc. |
11/20/2024 03:31 PM EST | SeekingAlpha | Q3 2024 Earnings: Hold Akebia Therapeutics |
10/03/2024 11:26 AM EDT | SeekingAlpha | Larimar started at outperform by Wedbush on FA drug candidate |
10/03/2024 09:59 AM EDT | KlickAnalytics | LRMR Price Target Alert: $22.00. Issued by Wedbush |
Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.